Research and Markets: Avastin (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/rkw3lf/avastin_macular) has announced the addition of the "Avastin (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023" report to their offering.

Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

Avastin is active against all isoforms of VEGF-A, and can prevent it from interacting with its receptors on the surface of endothelial cells, which leads to the inhibition of angiogenesis, a key feature of both wAMD and DME. Therefore, in addition to its approved therapeutic role as an oncology drug, Avastin has been used off-label for many years as an IVT anti-VEGF treatment for these retinal diseases, despite the launch of Lucentis (a mAb fragment derived from the same parent murine antibody as Avastin) in 2006 for wAMD, which was also developed by Genentech.

Scope

- Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Avastin including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Avastin for the top seven countries from 2013 to 2023.

- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

3.1 Macular Degeneration Overview

3.2 Macular Edema Overview

4 Disease Management

4.1 Diagnosis and Treatment Overview

4.1.1 Macular Edema Diagnosis

4.1.2 Macular Degeneration Diagnosis

4.1.3 Treatment Guidelines and Leading Prescribed Drugs

4.1.4 Clinical Practice

5 Competitive Assessment

6 Avastin (bevacizumab)

6.1 Overview

6.2 Efficacy - Macular Degeneration

6.3 Efficacy - Macular Edema

6.4 Safety

6.5 SWOT Analysis

6.6 Forecast

7 Appendix

For more information visit http://www.researchandmarkets.com/research/rkw3lf/avastin_macular

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals